Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-THK5317
- Development stage
- Unknown
- Lead developer
- Tohoku University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-THK5317 is a radiopharmaceutical used as a positron emission tomography (PET) imaging agent for the in vivo detection of tau protein aggregates in the brain. It is primarily developed as a biomarker for Alzheimer's disease and related tauopathies. The compound binds to neurofibrillary tangles composed of hyperphosphorylated tau protein, allowing visualization and quantification of tau pathology in patients. Studies have shown that 18F-THK5317 can discriminate between healthy controls, prodromal Alzheimer's disease, and Alzheimer's dementia groups with high accuracy. Additionally, early-phase imaging with this tracer provides information on brain perfusion closely related to glucose metabolism. The tracer has been evaluated head-to-head against other tau PET tracers such as 18F-flortaucipir and has demonstrated strong predictive value for cognitive decline in Alzheimer’s disease patients[1][5][6][7].
- Other names
- (S)-[18F]THK5117
02
Targets
MAOB (Monoamine oxidase B)Tau aggregates (Microtubule-associated protein tau (pathological form))
Beyond the preview
Go deeper on 18F-THK5317.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-THK5317.